Vladimir Bystricky

Vladimir Bystricky asked if ITT has observed any changes in competitive behavior within its Industrial Process (IP) business, particularly regarding potential risks from more aggressive competition on pricing or terms and conditions. He also inquired about incremental opportunities and the pipeline in the biopharma valves market, specifically for potential wins in 2026, given positive capital investment trends in pharma.

Answer

CEO Luca Savi stated that there has been no change in competitive behavior in the IP segment over the last six years. He attributed ITT's outperformance to continuously improving execution, citing project business margins in the high 20s and on-time delivery, which fosters customer loyalty. CFO Emmanuel Caprais detailed the biopharma valves opportunity, noting the GLP-1 business has grown from a $20 million award to over $50 million due to customer expansion in the US and Europe. He highlighted the recurring aftermarket for diaphragm replacements and mentioned that the biopharma valves business orders were up 10% in 2025. Emmanuel also pointed out significant untapped opportunities in Europe and the strong growth of Habonim (now over $60 million, up from $50 million when acquired) in new energy, with good margins.

Vladimir Bystricky asked if ITT has observed any changes in competitive behavior within its Industrial Process (IP) business, particularly regarding pricing or terms and conditions. He then inquired about incremental opportunities and the pipeline in the biopharma valves market, specifically for potential wins in 2026, following the success with a GLP-1 drug maker.

Answer

CEO Luca Savi stated there has been no change in competitive behavior in IP over the last six years, attributing ITT's outperformance to continuously improving project execution, which delivers high 20s margins and fosters customer loyalty. CFO Emmanuel Caprais detailed the GLP-1 opportunity growing from $20 million to over $50 million, with significant recurring aftermarket potential. He noted the biopharma valves business orders were up 10% this year, with substantial opportunities in less-penetrated European markets and continued growth from Habonim, which is now a $60 million+ business.